Triphenylalkene derivatives and their use as selective...

Details Triphenylalkene derivatives and their use as selective... Triphenylalkene derivatives and their use as selective...

2005-04-05

2005-04-05

Rotman, Alan L. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S331000, C514S396000, C514S428000, C514S644000, C514S648000, C514S651000, C514S720000, C514S724000, C546S192000, C546S229000, C546S232000, C546S234000, C546S236000, C546S239000, C546S240000, C548S300100, C548S515000, C564S324000

Reexamination Certificate

active

06875775

ABSTRACT:
The invention provides novel selective estrogen receptor modulator compounds of the general formula:wherein R1 and R2, which are the same or different area) H, halogen, OCH3, OH; orwhere X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C≡CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; orc) —Y—(CH2)nCH2—O—R6where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; ord) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or —OCH3;stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.

REFERENCES:
patent: 4536516 (1985-08-01), Harper et al.
patent: 4656187 (1987-04-01), Black et al.
patent: 4696949 (1987-09-01), Toivola et al.
patent: 4839155 (1989-06-01), McCague
patent: 4894373 (1990-01-01), Young
patent: 4996225 (1991-02-01), Toivola et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5192525 (1993-03-01), Yang et al.
patent: 5196435 (1993-03-01), Clemens et al.
patent: 5446203 (1995-08-01), McNelis
patent: 5470883 (1995-11-01), Stromberg
patent: 5491173 (1996-02-01), Toivola et al.
patent: 5658931 (1997-08-01), Bryant et al.
patent: 5691355 (1997-11-01), Bryant et al.
patent: 5693674 (1997-12-01), Bitonti
patent: 5719136 (1998-02-01), Chwalisz et al.
patent: 5807899 (1998-09-01), Bohlmann et al.
patent: 5821254 (1998-10-01), Sporn et al.
patent: 5827892 (1998-10-01), Löser et al.
patent: 5852059 (1998-12-01), Thompson
patent: 5877219 (1999-03-01), Willson
patent: 5912273 (1999-06-01), Degregorio et al.
patent: 6037379 (2000-03-01), Harkonen et al.
patent: 6576645 (2003-06-01), Sodervall et al.
patent: 0 095 875 (1983-12-01), None
patent: 1064629 (1967-04-01), None
patent: WO 9206068 (1992-04-01), None
patent: WO 9319746 (1993-10-01), None
patent: WO 9526720 (1995-10-01), None
patent: WO 9607402 (1996-03-01), None
patent: WO 9635417 (1996-11-01), None
patent: WO 9640616 (1996-12-01), None
patent: WO 9732574 (1997-09-01), None
patent: 0 779 808 (1999-08-01), None
patent: WO 9942427 (1999-08-01), None
patent: WO 9963974 (1999-12-01), None
Budavari, S. et al., eds.,The Merck Index, Eleventh Edition, p. 1430, No. 9039, Merck & Co., Inc., Rathway, NJ, USA (1989).
Goldstein, S.R. et al., “A pharmacological review of selective oestrogen receptor modulators,”Human Reproduction Update6:212-224, Oxford University Press (May-Jun. 2000).
Grodstein, F. and Stampfer, M.J., “Estrogen for women at varying risk of coronary disease,”Maturitas30:19-26, Elsevier Science Ireland Ltd. (Sep. 1998).
Henderson, V.W., “Estrogen, Cognition, and a Woman's Risk of Alzheimer's Disease,”The American Journal of Medicine103:115-185, Excerpta Medica, Inc. (1997).
Kangas, L. et al., “Bioluminescence of Cellular ATP: A New Method for Evaluating Cytotoxic Agents In Vitro,”Medical Biology62:338-343, Duodecim (1984).
Kangas, L. et al., “A new triphenylethylene compound, Fc-1157a: II. Anti effects,”Cancer Chemother. Pharmacol. 17:109-113, Springer-Verlag (1986).
Kangas, L., “Biochemical and pharmacological effects of toremifene metabolites,”Cancer Chemother. Pharmacol. 27:8-12, Springer-Verlag (1990).
Khovidhunkit, W. and Shoback, D.M., “Clinical Effects of Raloxifene Hydrochloride in Women,”Ann. Intern. Med.130:431-439, American College of Physicians (Mar. 1999).
Lobo, R.A., “Benefits and risks of estrogen replacement therapy,”Am. J. Obater. Gynecol. 173:982-989, Mosby-Year Book, Inc. (1995).
Macgregor, J.I. and Jordan, V.C., “Basic Guide to the Mechanisms of Antiestrogen Action,”Pharmacol. Rev.50:151-196, Williams and Wilkins Co. (Jun. 1998).
Peng, Z. et al., “The Mechanical Strength of Bone in Different Rat Model: Experimental Osteoporosis,”Bone15:523-532, Elsevier Science Ltd. (1994).
Plouffe, L., “Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice,”J. Soc. Gynecol. Investig. 7:S38-S46, Elsevier Science Inc. (Jan.-Feb. 2000).
Qu, Q. et al., “Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats,”Endocrinology141:809-820, Association for the Study of Internal Secretions (Feb. 2000).
Simberg, N.H. et al., “In Vitro and In Vitro Binding of Toremifene and Its Metabolites in Rat Uterus,”J. Steroid Biochem. 36:197-202, Pergamon Press: plc (1990).
Terenius, L., “Structure-Activity Relationships of Anti-Oestrogens With Regard to Interaction with 17μ-Oestradol in the Mouse Uterus and Vagina,” Acta Endocrinol. 66:431-447, Scandinavian University Press (1971).
International Search Report for corresponding International Application No. PCT/FI00/00946, mailed Feb. 8, 2001.

Affiliated with

Also associated with

Rating

Triphenylalkene derivatives and their use as selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Triphenylalkene derivatives and their use as selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triphenylalkene derivatives and their use as selective... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3442158